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The therapeutic approach to cancer is complex and multidisciplinary
[1–3], and radiotherapy is among the essential treatments, whether
used alone or in conjunction with other therapies (e.g., chemother-
apy, surgery). About 50% of cancer patients need radiotherapy as part
of their treatment plan [4], according to scientific evidence. To
guarantee its quality, safety, and effectiveness, providers must apply
strict quality control measures during administration of the therapy to
minimize risks to the patient. Ideally, there should be monitoring
systems in place throughout the radiation oncology process in order
to check critical points with regard to the clinical appropriateness,
safety, and effectiveness of treatments with ionizing radiation.
Numerous scientific societies and organizations specifically recom-
mend conducting audits in these settings as a way to evaluate these
quality criteria [5,6]. Moreover, variability in clinical practice [7] is a
relevant factor that can affect patients’ clinical results.
Some authors have proposed general indicators to assess the quality
of the radiotherapeutic process [8,9] or specific ones related to rectal
cancer [10], and recently, the International Consortium for Health
Outcomes Measurement [11] has also put forward a set of indicators
focused on the impact of treatment and quality of life in patients with
colorectal cancer. However, for the most part, there are no available
indicators with international validity that could serve as a reference for
comparing radiation oncology services.This study aims to design a clinical audit model that defines a set of
specific indicators for each of the four priority pathologies (cancers of the
rectum, prostate, lung, and cervix) that enables the assessment of key areas
of the treatment process: diagnosis, treatment, posttreatment follow-up,
and clinical outcomes. In this way, we intended to obtain information on
the clinical efficacy of the treatments, evaluate adherence to agreed
protocols, and measure the variability among the three participating
departments of radiation oncology; our findings will inform the
development of objectives to improve therapeutic quality based on
mutual learning. This paper presents the results obtained for rectal cancer.
Methods
Study Framework




Table 1. General Indicators of Center Operation (2014 Data)
Center A Center B Center C
Quality management systems




Care protocols and organization
Existence of a multidisciplinary
committee to agree on therapeutic approach
Yes Yes Yes
Number of members in multidisciplinary committee Variable between 3 centers
Existence of a clinical session to
evaluate the indication for radiotherapy
Yes Yes Yes
Number of members in clinical session Variable between 3 centers
Existence of clinical practice
guidelines by pathology
Yes, unified between centers
Existence of a protocol for imaging verification Yes, partially. Not unified
between centers.
Existence of a protocol for
treatment interruptions
Yes, partially. Not unified
between centers.
Perceived quality
Overall satisfaction with care received is ≥8/10 92.14% 91.85% 92.55%
Center operation perceived as perfect or very good 94.25% 83.3% 84.58%
Professionals (do not include brachytherapy)
Ratio external beam radiotherapy
treatments per radiation oncologist
188.07 169.33 191.86




Care activity (does not include brachytherapy)
External beam radiotherapy treatments 2539 1524 1343




Impact factor (articles published per year) 13,624.00 3607.00 2635
Percentage of patients included in clinical trials with
participation of RT and/or medical physics service(s)
1.41% 0.6% 0.01%
EBRT, external beam radiotherapy; BQT, brachytherapy.
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with three centers offering radiation oncology treatments in
cooperation with three university hospitals. Additionally, ICO
works in a network with 17 local hospitals, making it the reference
center in cancer care for 2.5 million people (40% of the population of
Catalonia). Its care model is characterized by its multidisciplinary
focus by pathology and the standardized care based on clinical
practice guidelines, developed through corporate consensus. The
three radiation oncology departments are ISO-certified (2003, 2005,
and 2008). At the time of the study, clinical practice guidelines for
colorectal cancer were in place (approved in December 2012), with
two radiotherapy treatments detailed: short-course radiotherapy
(SCRT), indicated for patients aged 70 years or older and those
with tumors in the middle third of the rectum or without
involvement of the mesorectal fascia, and long-course radiotherapy
(LCRT), indicated for all other cases.
Design
This is a multicenter retrospective cohort study in a representative
sample of patients diagnosed with rectal cancer. To design the study,
we formed a working group of radiation oncologists, medical
physicists, and technologists from the three participating centers,
led by the senior clinician in rectal cancer. We identified the key areas
for assessment, including the diagnostic, treatment, and follow-up
phase, based on the reviewed literature [8,9] and a previous study that
ICO performed in collaboration with the Wielkospolskie Centrum
Onkologii group [10].
The set of indicators we developed assessed the appropriateness of
the tests performed and the quality of the diagnostic reports,
particularly the notation of the distance from the tumor to the
mesorectal fascia (rCRM), based on high-resolution magnetic
resonance imaging (MRI). Other indicators included the presentation
of cases to a multidisciplinary committee to validate the treatment,
appropriateness and degree of adherence to the prescribed treatment
(dose and duration of radiotherapy), number of imaging verifications
conducted during the radiotherapy sessions, the postoperative
circumferential resection margin (ypCRM), the clinical follow-up
carried out in the center, adverse effects recorded over the course of
treatment [and whether these were classified according to the
Common Terminology Criteria for Adverse Events (CTCAE) version
4.0] [12], and overall survival at 4 years.
Clinical Audit
The second phase of the study was the clinical audit, which
consisted of a review of a random sample of 40 clinical histories for
each center. The target population for the study was patients
diagnosed with rectal cancer (RE: CIM-9:154.1) who in 2013
received neoadjuvant radiotherapy with a curative intent. The audit
took place from June to September of 2015 and was carried out by
evaluators who were not affiliated with the participating centers in
order to avoid bias in interpreting the information contained in the
clinical histories and to maintain consistency in the data collection.
The form used to collect the data was prepiloted to test its validity.
The source of the data consisted of the electronic medical records used
in the centers throughout the care pathway and which are available to
all professionals working in all centers. The specific information
system for radiotherapy was also accessed to complete the prespecified
data collection process. To calculate overall survival, in February
2017, we updated our data on the vital status of all patients includedin the study. To complete the audit and with the aim of assessing the
overall functioning of each center, we collected additional informa-
tion on organizational indicators (existence of committees and clinical
sessions), quality certification systems, availability of consensus-based
protocols, research and care activity, available equipment, perceived
quality, and patient satisfaction. We obtained this information from
corporate information systems and meetings between the auditing
team and the participating services.
We performed the statistical analysis during the fourth quarter of
2015 using SPSS statistical software (IBM, Armonk, NY). Sample size
was calculated to achieve a level of confidence of 0.95 (alpha 0.05),
assuming a finite population of about 100 cases per center and an
attrition rate of 50%. To compare results between centers, we used the
χ2 test for qualitative variables and the ANOVA test for qualitative
variables. To calculate survival, we used the Cox regression model,
adjusted for center, sex, age group, and tumor stage at diagnosis.
Results
Table 1 presents the profile of overall functioning, the organization
and protocolization of care, and research and treatment activity in
each center. The clinical characteristics and results for the indicators
in the diagnostic stage are described in Table 2, while Table 3 shows
those for the treatment and follow-up phases. The demographic
profile, histology, and staging of patients were similar, and we did not
observe any significant differences between centers. Overall, 71.7% of
patients were men and 28.3% women, and the mean age was 67.23
years. Virtually all patients (99.2%) had an invasive carcinoma, and
Table 2. Characteristics of Cases Reviewed and Quality Indicators (2013) a, †
Rectal Cancer Center A Center B Center C Total ICO
n % n % n % n % P
Total cases included 40 33.3% 40 33.3% 40 33.3% 120 100%
Sex Men 30 75.0 29 72.5 27 67.5 86 71.7 0.750
Women 10 25.0 11 27.5 13 32.5 34 28.3
Age (years) b60 28 23.3 6 15.0 9 22.5 13 32.5 0.532
60-69 42 35.0 15 37.5 16 40.0 11 27.5
70-79 40 33.3 14 35.0 13 32.5 13 32.5
≥80 10 8.3 5 12.5 2 5.0 3 7.5
Histology Squamous cell carcinoma 1 2.5 · · · · 1 .8 0.365
Invasive adenocarcinoma 39 97.5 40 100 40 100 119 99.2
Histological grade Well differentiated 17 42.5 9 22.5 17 42.5 43 35.8 0.005*
Moderately differentiated 10 25.0 3 7.5 7 17.5 20 16.7
Poorly differentiated 3 7.5 1 2.5 · · 4 3.3
Missing † 10 25.0 27 67.5 16 40.0 53 44.2
Percentage of patients undergoing MRI Yes 36 90.0 38 95.0 40 100.0 114 95.0
No 4 10.0 2 5.0 6 5.0 0.122
Distance from tumor to anal verge 0-5 cm 9 22.5 2 5.0 13 32.5 24 20.0 b0.001*
5-10 cm 19 47.5 7 17.5 15 37.5 41 34.2
N10 cm 6 15.0 11 27.5 17 14.2
Missing † 6 15.0 31 77.5 1 2.5 38 31.7
Distance from tumor to
mesorectal fascia (mm) (rCRM)
≤1 mm 6 15.0 9 22.5 14 35.0 29 24.2 0.013*
N1 mm 12 30.0 14 35.0 19 47.5 45 37.5
Missing † 22 55.0 17 42.5 7 17.5 46 38.3
TNM staging (presurgical) II 3 7.7 6 15.0 5 12.5 14 11.8 0.666
III 33 84.6 29 72.5 31 77.5 93 78.2
IV 3 7.7 5 12.5 4 10.0 12 10.1
Missing † 1 1
Percentage of patients diagnosed in ICO Yes 5 12.5 29 72.5 10 25 44 36.7 b0.001*
No 31 77.5 10 25.0 30 75.0 71 59.2
Missing † 4 10.0 1 2.5 0 0.0 5 4.2
Percentage of cases presented in multidisciplinary
committee to evaluate initial treatment plan
Yes 19 47.5 29 72.5 28 70.0 76 63.3
No 20 50.0 11 27.5 12 30.0 43 35.8 0.1
Missing † 1 2.5 1 .8
Percentage of patients diagnosed at
ICO and presented at multidisciplinary
committee to evaluate initial treatment plan
Yes 4 80.0 25 86.2 10 100.0 39 88.6
No 1 20.0 4 13.8 5 11.4 0.402
Percentage of patients presented
at clinical session in radiation oncology
service prior to initiating RT
Yes 36 90.0 37 92.5 40 100.0 113 94.2
No 2 5.0 3 7.5 5 4.2 0.134
Missing † 2 5.0 2 1.7
a TNM Classification of Malignant Tumours (UICC) (Five edition, 1997)
† No data found in the medical records.
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patients underwent an MRI, with no significant differences between
centers, although there were qualitative differences in the clinical
information recorded in the corresponding report. One center
recorded the distance from the tumor to the anal verge in 97.5% of
the cases compared to 85% and 22.5% in the other centers. The
reports did not include the rCRM in 38.3% of the cases; by center,
this value was recorded in 82.5%, 57.5%, and 45% of the reports.
Ninety percent of the patients received LCRT, while just 12 patients
(10%) were treated with SCRT.
Most (96.7%) patients received the planned dose, and 57.4%
received it at the planned time (±2 days). There were significant
differences with regard to the latter indicator, with one center never
lengthening the treatment period for more than 5 days and the other
two centers doing so in 25% and 16.6% of the cases, respectively. In
the 46 cases where there was an interruption in the treatment, the
most common reasons were public holidays (78.7%) and technical
difficulties (31.9%). None of the patients who received SCRT
experienced interruptions.
Surgery followed neoadjuvant treatment in 96.7% of the patients.
Among this group, postoperative CRMwas recorded in 65.5% (n = 76)
of the cases and was negative in 93.4% of these. With regard to the34.5% (n = 40) of cases where no CRM value was stated, there were
differences between the centers: 83.3% of the reports from one center
contained this information, while 74.4% and 40% of the reports from
the other two centers did. Of the total sample, clinical histories showed
that 5% of the patients experienced adverse events of grade III or higher
according to the CTCAE (v 4.0)12. Mean follow-up was 3.4 (SD 0.6)
years, and overall survival at 4 years was 81.7%. After adjusting for age,
sex, and tumor stage, there were no statistically significant differences
between centers in this regard (P = .223, Table 4, Figure 1).
Discussion
This study brings to light the existence of considerable variability in
clinical practice [7,13] among three centers working with the same
care protocols, demonstrating that consensus-based clinical practice
guidelines and ISO certification are not enough; systematic
monitoring and evaluation of each planned change are required to
achieve the desired adherence.
For rectal cancer, the therapeutic strategy includes determining
which patients are at the most risk, and high-resolution MRI is the
most accurate technique, allowing us to identify the mesorectal fascia
and its relation with the tumor front with a specificity of 92% [14].
The distance from the tumor to the mesorectal fascia (rCRM) is
Table 3. Treatment Phase and Oncological Follow-Up. Quality Indicators (2013) g
Rectal Cancer Center A Center B Center C Total ICO
n % n % n % n % P
Treatment phase
Distribution of patients according to treatment received Chemo + concomitant RT + surgery 39 97.5 37 92.5 37 92.5 113 94.2 0.225
RT + surgery 1 2.5 3 7.5 1 2.5 5 4.2
RT + chemo 2 5.0 2 1.7
Type of radiotherapy SCRT 8 20.0 4 10.0 · · 12 10.0 0.012*
LCRT 32 80.0 36 90.0 40 100 108 90.0
Total prescribed dose (Gy) SCRT (25.00 Gy) 8 20.0 4 10.0 · · 12 10.0 b0.001*
LCRT (45.00 Gy) · · 36 90.0 · · 36 30.0
LCRT (50-54 Gy) 32 80 0 0 40 100 72 60
Treatment technique indicated 3D 37 92.5 40 100 40 100 117 97.5 0.188
VMAT 1 2.5 · · · · 1 .8
IMRT 2 5.0 · · · · 2 1.7
Percentage of patients completing
planned treatment (dose)
Yes 39 97.5 38 95.0 39 97.5 116 96.7 0.772
No 1 2.5 2 5.0 1 2.5 4 3.3
Percentage of patients suffering
interruptions according to the days
treatment was prolonged (LCRT)
b3 days 12 37.5 19 52.7 31 77.5 62 57.4 0.006*
3-5 days 12 37.5 11 30.5 9 22.5 32 29.6
6-10 days 8 25.0 3 8.3 0 0 11 10.2
N10 days 0 0.0 3 8.3 0 0 3 2.8
Percentage of patients undergoing restaging MRI Yes 8 20.0 0 0.0 31 77.5 39 32.5 0.001*
No 32 80.0 40 100.0 9 22.5 81 67.5
Percentage of patients with indication for
surgical treatment following primary
treatment (chemo and/or RT)
Yes 39 97.5 40 100.0 37 92.5 116 96.7 0.087
No 3 7.5 3 2.5
Missing 1 2.5 1 .8
Percentage of patients according to
radial margin result (ypCRM)
Positive 1 2.6 1 2.5 3 8.1 5 4.3 0.001*
Negative 28 71.8 15 37.5 28 75.7 71 61.2
Missing 10 25.6 24 60.0 6 16.2 40 34.5
Percentage of patients undergoing surgery
in ICO who had been previously presented
in multidisciplinary committee to
assess response to primary treatment
Yes 8 100 23 69.7 21 72.4 52 74.3
No 10 30.3 8 27.6 18 25.7 0.203
Follow-Up Phase
Percentage of patients experiencing serious
(Ngrade II) RT-related adverse effects
Yes 1 2.5 3 7.5 2 5.0 6 5.0 0.591
No 39 97.5 37 92.5 38 95.0 114 95.0
Percentage of patients with recorded follow-up in ICO Yes 36 90.0 37 92.5 39 97.5 112 93.3 0.392
No 4 10.0 3 7.5 1 2.5 8 6.7
Chemo, chemotherapy; RT, radiotherapy; VMAT, volumetric arc therapy; IMRT, intensity-modulated radiation therapy.
g No data found in the medical records.
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show considerable room for improvement: even though all the
patients had an MRI, the medical records of 38.3% did not contain
information on this parameter either in the diagnostic report or over
the clinical course, making it a prime target for improvements. The
relevance of this indicator has been recognized, for example, in the
work of the Mercury Group [15], which reported that the rate of
recurrence ranges from 53% in tumors with a potential margin of less
than 1 mm of the CRM to 8% in patients with an rCRM of 8 mm or
more.
In the treatment phase, adherence to clinical practice guidelines
regarding the type of radiotherapy prescribed (LCRT versus SCRT)
was rather low: 12 patients (10%) were indicated for SCRT, but 6 did
not meet the pertinent criteria. Of the 9 patients who did meet the
criteria for SCRT, only 6 (66.7%) received it. Although the
indication of one technique over another has not been linked to
local control, survival, late toxicity, or quality of life [16], the
advantage of SCRT over LCRT lies in the simplicity of its
administration and patients’ reduced dependency on the hospital.
Moreover, regarding adherence to the planned treatment, the results
are not optimal either, especially in one center. We observed that
13% of the cases were prolonged more than 5 days over the initial
plan. Numerous studies directly relate local control of the tumor with
the prolongation of radiotherapy [17–20]; Bese [21] found that forcancer of the head and neck, each day that treatment was interrupted
led to a decrease in local control of 1.4%. There is less evidence for
rectal cancer, but we consider that administration of radiotherapy
should rigorously adhere to the treatment plan and that it is
unacceptable to prolong it more than 5 days, especially when the
main reasons are avoidable organizational factors. As described in the
Royal College of Radiologist guidelines [22], which also apply here,
most interruptions are due to public holidays that fall on weekdays
and technical issues (machine inspections and breakdowns). These
factors are generally known well in advance, and staff should take
them into account when planning treatment. A range of options is
available to compensate for the negative effect of these interruptions,
but essentially, it is a question of developing and implementing a
protocol tailored to each center’s circumstances. Updating the
protocol and regularly monitoring this indicator are actions that we
use to improve adherence to planned radiotherapy treatment. Overall,
the degree of adherence to clinical practice guidelines could be
significantly better. We believe that a reasonable mechanism to
improve it would be automated alerts and reminders—referring to
consensus-based indicators—sent to professionals at the clinical
station in order to support the decision-making process. This
approach has led to improvements in other clinical settings [23,24].
Finally, the other indicator considered crucial due to its prognostic
value in patients’ evolution is the result of the ypCRM [25]. We
Table 4. Analysis of Time to Death or Date of Last Follow-Up (Stage I Cases Omitted) 1
Exitus
Multivariate
n total % exitus HR (95%CI) P
Center Center A 40 20.0 1 0.223
Center B 40 12.5 0.47 (0.15-1.45) 0.191
Center C 40 22.5 1.24 (0.47-3.23) 0.666
Sex Men 86 22.1 1
Women 34 8.8 0.33 (0.10-1.15) 0.081
Age (years) b60 28 21.4 1 0.272
60-69 42 9.5 0.34 (0.09-1.29) 0.113
70-79 40 25.0 1.04 (0.35-3.06) 0.949
≥80 10 20.0 1.06 (0.19-5.86) 0.943
Stage II 14 28.6 1 0.573
III 93 15.1 0.59 (0.18-1.88) 0.372
IV 12 33.3 1.30 (0.30-5.58) 0.723
Missing 1 0.0 (-) 0.981
Dash (-) used when HR and 95% CI could not be calculated.
1 Specification cox model (statistical). This model collect the mortality for 4 years adjusted by center, sex,
age group and stage.
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ypCRM margin, compared to the 8% to 13% in other published
reports [26,27], suggesting good results. However, and as with the
rCRM value, the ypCRM values for 34.5% of the patients who
underwent surgery are unknown. While other studies have reported
similar percentages [28], we have launched several actions for
improvement. We believe that the tumor board sessions are
invaluable, and in addition to using this time to reach a consensus
on each patient’s treatment plan, it should be used to emphasize the
importance of everyone on the multidisciplinary team being able to
access CRM data, which in this case implies that the anatomical
pathology and diagnostic imaging services should add these data to
their respective reports.
With regard to the clinical results, it is difficult to assess the adverse
effects, in part because the design of the questionnaire did not allow
any differentiation between acute and chronic events but mostly
because the poor quality of the notes taken over the clinical course
made grading the severity of the effects difficult. Without a doubt,Figure 1. Survival functions with Cox multivariate model.adopting a registration system with structured data would produce
more objective and internationally comparable data [29]. Further-
more, we confirmed the scant references to certain adverse effects,
especially those related to the sexual sphere or sphincter control; the
presence (or absence) of these effects should clearly be noted in the
clinical histories. In fact, the questionnaire does not include any items
related to quality of life, which we consider to be a limitation of the
study to be rectified in future audits. There is no question that
awareness among professionals should be raised with regard to
monitoring patients’ quality of life, and we believe that the use of a
validated questionnaire in these patients could be useful for
systematizing an essential dimension of clinical results [11,30].
Other study limitations relate to the design of the audit itself, as the
sample of just 40 medical histories limits our assessment of the results
and the comparison between centers, particularly for indicators on
clinical results. Moreover, the period analyzed, 2013, was chosen so
that we could assess all phases of the process, including follow-up and
4-year survival; however, some results have changed considerably
since then. As with any review of clinical histories, the data are derived
from the information contained in clinical registries, and any
considerations not recorded there are also absent from the audit.
In conclusion, the audit we performed revealed a suboptimal
degree of adherence to clinical practice guidelines for rectal cancer.
Significant variability between centers exists from a clinical
perspective but especially with regard to organization and process.
In that sense, the value of a clinical audit like the one performed
resides in its power to shed light on the need for improvement in
areas that may otherwise have been considered resolved. Addition-
ally, the audit raises questions about how to improve adherence to
guidelines, what value professional consensus confers, and how to
translate that consensus to practice during patient care. Clearly, the
approval of a document by a group of experts is insufficient. We
believe that using information and communication technologies in
the form of automated guidelines to aid professionals at the clinical
station could be the way to improve adherence. In any case,
measuring and evaluating performance through a clinical audit are
the first steps for improving clinical processes for the benefit of our
patients.
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